Recipharm completes divestment of seven sites

Recipharm, a leading global contract development and manufacturing organisation, today announced the completion of the divestment of seven sites to Blue Wolf Capital Partners. The sites included in the sale are in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden; Pessac in France; and Parets in Spain.

As announced in April 2024, this announcement marks a significant milestone in Recipharm's journey to sharpen its focus on core segments:  Oral Solids Dosage for new chemical entities, medium to high potency and on-patent drugs; Advanced Therapy Medicinal Products (ATMPs, its ReciBioPharm segment); and Sterile Fill & Finish.

As it continues to drive innovation and excellence in contract development and manufacturing, the company remains dedicated to meeting the evolving needs of its clients and the industry through its 18 sites across France, Germany, India, Italy, Israel, Portugal, Spain, Sweden and the US.